ASCO 2026: a major breakthrough for advanced prostate cancer
June 1st, 2026 Centre Oscar Lambret :
"On May 30, a study led by Prof. Karim Fizazi, Chief Executive Officer of the Center, was presented at the ASCO Congress in Chicago. The data unveiled at the congress show a highly significant clinical benefit. The prestigious New England Journal of Medicine also published these results simultaneously.
Coordinated by Prof. Karim Fizazi, medical oncologist and Chief Executive Officer of the Oscar Lambret Center, the international phase III TALAPRO‑3 trial demonstrates the major efficacy of a PARP inhibitor combined with a second‑generation hormone therapy as an initial treatment for metastatic prostate cancer.
Prostate cancer is the second leading cause of cancer‑related death in men worldwide, with 50,000 new cases per year in France. While hormonal treatments are usually effective at the metastatic stage, patients carrying genetic alterations (BRCA1, BRCA2, ATM, ATR, CDK12, CHEK2 genes, etc.) tend to develop more aggressive forms, with rapid progression and a poorer prognosis."
Read the full article here.
Comments0
Please log in to see or add a comment
Suggested Articles
